Arbutus Biopharma (Arbutus Biopharma) EBIT per Share : $-0.44 (TTM As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Arbutus Biopharma EBIT per Share?

Arbutus Biopharma's EBIT per Share for the three months ended in Mar. 2024 was $-0.10. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.44.

During the past 3 years, the average EBIT per Share Growth Rate was 14.60% per year. During the past 5 years, the average EBIT per Share Growth Rate was 21.20% per year. During the past 10 years, the average EBIT per Share Growth Rate was 9.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Arbutus Biopharma's EBIT per Share or its related term are showing as below:

ABUS' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -93.9 Med: 2.8 Max: 66.2
Current: 14.6

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Arbutus Biopharma was 66.20% per year. The lowest was -93.90% per year. And the median was 2.80% per year.

ABUS's 3-Year EBIT Growth Rate is ranked better than
65.21% of 1305 companies
in the Biotechnology industry
Industry Median: 3.5 vs ABUS: 14.60

Arbutus Biopharma's EBIT for the three months ended in Mar. 2024 was $-17.83 Mil.

Arbutus Biopharma EBIT per Share Historical Data

The historical data trend for Arbutus Biopharma's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arbutus Biopharma EBIT per Share Chart

Arbutus Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-2.88

-0.79

-0.69

-0.42

-0.44

Arbutus Biopharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															-0.10	-0.10	-0.12	-0.11	-0.10

Arbutus Biopharma EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Arbutus Biopharma's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-72.39	/	165.960
=	-0.44

Arbutus Biopharma's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-17.831	/	175.626
=	-0.10

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.44

Arbutus Biopharma (NAS:ABUS) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Arbutus Biopharma EBIT per Share Related Terms

Thank you for viewing the detailed overview of Arbutus Biopharma's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Arbutus Biopharma (Arbutus Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arbutus Biopharma Corp (NAS:ABUS) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

I9DN:Germany

Address

701 Veterans Circle, Warminster, PA, USA, 18974

Website

http://www.arbutusbio.com

Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.

Executives

Melissa Rewolinski	director	9000 STATE ROAD, PHILADELPHIA PA 19136
Karen Sims	officer: Chief Medical Officer	701 VETERANS CIRCLE, WARMINSTER PA 18974
J. Christopher Naftzger	officer: General Counsel and CCO	633 LOWTHER ROAD, LEWISBERRY PA 17339
Michael J. Sofia	officer: Chief Scientific Officer	C/O ARBUTUS BIOPHARMA CORP., SUITE 100, 8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
Tram Tran	director	C/O ARBUTUS BIOPHARMA CORPORATION, 701 VETERANS CIRCLE, WARMINSTER PA 18974
Roivant Sciences Ltd.	10 percent owner	CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Michael J. Mcelhaugh	officer: Chief Business Officer	C/O ONCORE BIOPHARMA, INC., 3805 OLD EASTON ROAD, DOYLESTOWN PA 18902
Eric Venker	director	C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
James R Meyers	director	GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Andrew Cheng	director	170 HARBOR WAY, 3RD FLOOR, C/O AKERO THERAPEUTICS, INC., SOUTH SAN FRANCISCO CA 94080
Myrtle S Potter	director	10 FINDERNE AVE, BRIDGEWATER NJ 08807
William H. Collier	director, officer: President and CEO	C/O ARBUTUS BIOPHARMA CORPORATION, 701 VETERANS CIRCLE, WARMINSTER PA 18974
Elizabeth Howard	officer: Executive VP & General Counsel	100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
David C Hastings	officer: Chief Financial Officer	C/O ARBUTUS BIOPHARMA, 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
Gaston Picchio	officer: Chief Development Officer	C/O ARBUTUS BIOPHARMA CORP, 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8